<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04339907</url>
  </required_header>
  <id_info>
    <org_study_id>20.004</org_study_id>
    <nct_id>NCT04339907</nct_id>
  </id_info>
  <brief_title>Inflammatory Mediators of Glaucoma After Corneal Transplantation (AqueousHumor)</brief_title>
  <acronym>AqueousHumor</acronym>
  <official_title>Uncovering Inflammatory Mediators of Glaucoma Pathogenesis After Corneal Transplantation in Aqueous Humor and Tears</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glaucoma is the most common threat to vision rehabilitation in patients with Boston
      keratoprosthesis type 1 (KPro) implantation. High intraocular pressure (IOP) is the most
      important risk factor for glaucoma and may lead to irreversible retinal and optic nerve
      damage. Glaucoma drainage device (GDD) surgery is used to divert aqueous humor (AH) from the
      anterior chamber to an external reservoir to regulate flow and decrease the IOP. The AH is in
      direct communication with any corneal damage or surgery undertaken in the anterior chamber
      and can serve as a source of potential biomarkers to detect early inflammatory or
      glaucomatous changes. Tears are also one of the most accessible and non-invasive source of
      biomarkers, especially in Kpro eyes where the central optic allows communication between
      aqueous humor and the tears at the surface of the eye. The investigators propose to test the
      hypothesis that distinct inflammatory mediators in the AH and tears can serve as biomarkers
      for glaucoma development and progression after CT, making them specifically amenable to
      targeted treatment strategies to minimize vision loss.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The only curative treatment for corneal diseases that progress to vision loss is corneal
      transplantation (CT). Penetrating keratoplasty (PK) involves the surgical replacement of the
      host cornea with a donor cornea. In cases of graft failure with standard PK, the Boston
      keratoprosthesis (KPro), the most common artificial cornea, can alternatively restore vision
      rapidly. A current limitation in the use of KPro is that the vast majority of patients are at
      high risk of developing glaucoma. Glaucoma contributes to significant ocular morbidity after
      CT surgery and is the leading cause of irreversible vision loss after CT. High intraocular
      pressure (IOP) is the most important risk factor for glaucoma and may lead to irreversible
      retinal and optic nerve damage. Glaucoma is treated using drops or surgery to reduce IOP.
      When IOP-lowering drugs and laser surgery fail, glaucoma drainage device (GDD) surgery is
      used to divert aqueous humor (AH) from the anterior chamber to an external reservoir to
      regulate flow and decrease the IOP. The cause and mechanisms of glaucoma development and
      progression following CT are still unknown. Neuroinflammation has been suggested to play a
      key role in glaucomatous damage following CT. The role of inflammatory biomarkers in glaucoma
      pathogenesis after CT remains poorly understood and must be further studied. The AH is in
      direct communication with any corneal damage or surgery undertaken in the anterior chamber
      and can serve as a source of potential biomarkers to detect inflammatory changes in glaucoma.
      Tears are also one of the most accessible and non-invasive source of biomarkers, especially
      in Kpro eyes where the central optic allows communication between AH and the tears at the
      surface of the eye. Full thickness corneal transplantation (penetrating keratoplasty and
      Boston KPro) and intraocular surgeries for glaucoma, cataract and retina that are required by
      the participants of the study offer the opportunity to have access to the AH and tears in an
      accessible and safe way, without additional risks. These samples of AH and tears will be
      analyzed for multiple inflammatory mediators simultaneously.

      HYPOTHESIS:

      The investigators propose to test the hypothesis that distinct inflammatory mediators in the
      AH and tears can serve as biomarkers for glaucoma development and progression after CT,
      making them specifically amenable to targeted treatment strategies to minimize vision loss.

      OBJECTIVES:

        1. To examine the (a) presence and (b) concentration of inflammatory mediators in glaucoma
           after corneal transplantation.

        2. To examine the correlation between the presence and concentration of inflammatory
           mediators and clinical ophthalmological data and imaging collected prospectively in
           participants followed for 12 months.

        3. To examine the correlation between the inflammatory mediators found in aqueous humor and
           tears.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>5 groups will be compared:
participant needing cataract surgery without glaucoma
participant needing glaucoma filtration surgery without prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis)
participant needing corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis), with or without glaucoma
participant needing intraocular surgery (cataract, retina or glaucoma) with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis)
participant needing glaucoma filtration surgery with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis)</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of inflammatory mediators in aqueous humor</measure>
    <time_frame>Baseline</time_frame>
    <description>Concentration (pg/mL) of inflammatory mediators in aqueous humor measured by ELISA multiplex.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of inflammatory mediators in tears</measure>
    <time_frame>Baseline</time_frame>
    <description>Concentration (pg/mL) of inflammatory mediators in tears measured by ELISA multiplex.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between tears and aqueous humor</measure>
    <time_frame>Baseline</time_frame>
    <description>Correlation between the concentration of inflammatory mediators in tears and aqueous humor, determined by Spearman correlation test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of anterior structural changes</measure>
    <time_frame>Baseline, 3 months, 6 months, 12 months</time_frame>
    <description>Incidence of anterior structural changes in the eye (iris, iridocorneal angle, trabecular meshwork, cornea), evaluated by anterior segment optical coherence tomography (AS-OCT) imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of visual acuity through time</measure>
    <time_frame>Baseline, 3 months, 6 months, 12 months</time_frame>
    <description>Change of visual acuity at each time point compared to baseline visual acuity. The visual acuity is measured using the Snellen chart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with visual field loss of 30% or more</measure>
    <time_frame>Baseline, 3 months, 6 months, 12 months</time_frame>
    <description>Proportion of participants with visual field loss of 30% or more at each time point, measured using the automated Humphrey 24-2 visual field. The loss of 30% or more of visual field is calculated using the baseline test as reference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Baseline, 3 months, 6 months, 12 months</time_frame>
    <description>Evaluation of intraocular pressure (units of mmHg) at each time point using Goldman tonometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of posterior structural changes</measure>
    <time_frame>Baseline, 3 months, 6 months, 12 months</time_frame>
    <description>Incidence of posterior structural changes in the eye (optic nerve and retina), evaluated by spectral domain optical coherence tomography (SD-OCT) imaging.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Glaucoma</condition>
  <condition>Corneal Transplantation</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Cataract surgery only</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants needing cataract surgery, without glaucoma or any other corneal diseases.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glaucoma surgery only</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants needing glaucoma filtration surgery, without any prior corneal transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corneal transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants needing corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis), with or without glaucoma.
This allows analyzing samples at baseline (time 0), at the time of the corneal transplantation procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intraocular surgery following corneal transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants needing intraocular surgery (cataract, retina or glaucoma), with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis).
This allows analyzing samples during the potential development or progression of glaucoma in participants who have previously undergone corneal transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glaucoma surgery following corneal transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants needing glaucoma filtration surgery, with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis).
This allows analyzing samples once glaucoma is confirmed in participants who have previously undergone corneal transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sampling of tears</intervention_name>
    <description>Tears will be collected at the start of any of surgery for which the participant presents. It will be collected using a tear-wash method to allow for protein collection. 0.06 ml of saline solution 0.9% will be instilled on the ocular surface. The participants will turn their eyes with eyes closed. The tear-wash fluid will be collected from the inferior fornix of the eye using a micropipette. Tear-was fluid will be placed in codified tubes stored at -80 degrees.</description>
    <arm_group_label>Cataract surgery only</arm_group_label>
    <arm_group_label>Corneal transplantation</arm_group_label>
    <arm_group_label>Glaucoma surgery following corneal transplantation</arm_group_label>
    <arm_group_label>Glaucoma surgery only</arm_group_label>
    <arm_group_label>Intraocular surgery following corneal transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sampling of aqueous humor</intervention_name>
    <description>Aqueous humor will be collected at the start of any of surgery for which the participant presents. A paracentesis of the anterior chamber is a common first step in intraocular surgeries. Aqueous humor is then commonly diluted with viscoelastic material injected inside the anterior chamber to avoid collapse of the anterior chamber. This way, the aqueous humor is commonly diluted or replaced entirely by the viscoelastic material injected during intraocular surgeries. A volume of 0.1 ml of aqueous humor will be taken by paracentesis using a 30-gauge needle connected to a 1-ml syringe. It consists of less than half of the total volume of aqueous humor in the eye. Aqueous humor will be placed in codified tubes stored at -80 degrees.</description>
    <arm_group_label>Cataract surgery only</arm_group_label>
    <arm_group_label>Corneal transplantation</arm_group_label>
    <arm_group_label>Glaucoma surgery following corneal transplantation</arm_group_label>
    <arm_group_label>Glaucoma surgery only</arm_group_label>
    <arm_group_label>Intraocular surgery following corneal transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years old or older

          -  Informed consent

          -  Ability to be followed for the duration of the study

          -  Presence of ocular disease specified for each group

        Specific criteria for each group:

          -  Group 1 : need to have cataract surgery without glaucoma

          -  Group 2 : need to have glaucoma filtration surgery without prior corneal
             transplantation

          -  Group 3 : need to have corneal transplantation (penetrating keratoplasty or Boston
             keratoprosthesis), with or without glaucoma

          -  Group 4 : need to have intraocular surgery after prior corneal transplantation
             (penetrating keratoplasty or Boston keratoprosthesis)

          -  Group 5 : need to have glaucoma filtration surgery with prior corneal transplantation
             (penetrating keratoplasty or Boston keratoprosthesis)

        Exclusion Criteria:

          -  Aged less than 18 or more than 80 years old

          -  Inability to give informed consent

          -  Presence of ocular diseases other than those studied herein
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Younes Agoumi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mona Harissi-Dagher, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Catherine Tessier, M.Sc.</last_name>
    <phone>1-514-890-8000</phone>
    <phone_ext>11550</phone_ext>
    <email>marie-catherine.tessier.chum@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dominique Geoffrion, B.Sc.</last_name>
    <phone>1-514-890-8000</phone>
    <phone_ext>11550</phone_ext>
    <email>dominique.geoffrion@mail.mcgill.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal (CHUM)</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie-Catherine Tessier, M.Sc.</last_name>
      <phone>1-514-890-8000</phone>
      <phone_ext>11550</phone_ext>
      <email>marie-catherine.tessier.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Younes Agoumi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mona Harissi-Dagher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Szigiato AA, Bostan C, Nayman T, Harissi-Dagher M. Long-term visual outcomes of the Boston type I keratoprosthesis in Canada. Br J Ophthalmol. 2020 Feb 17. pii: bjophthalmol-2019-315345. doi: 10.1136/bjophthalmol-2019-315345. [Epub ahead of print]</citation>
    <PMID>32066560</PMID>
  </reference>
  <reference>
    <citation>Wang Q, Harissi-Dagher M. Characteristics and management of patients with Boston type 1 keratoprosthesis explantation--the University of Montreal Hospital Center experience. Am J Ophthalmol. 2014 Dec;158(6):1297-1304.e1. doi: 10.1016/j.ajo.2014.08.037. Epub 2014 Aug 28.</citation>
    <PMID>25174898</PMID>
  </reference>
  <reference>
    <citation>Crnej A, Paschalis EI, Salvador-Culla B, Tauber A, Drnovsek-Olup B, Shen LQ, Dohlman CH. Glaucoma progression and role of glaucoma surgery in patients with Boston keratoprosthesis. Cornea. 2014 Apr;33(4):349-54. doi: 10.1097/ICO.0000000000000067.</citation>
    <PMID>24531120</PMID>
  </reference>
  <reference>
    <citation>Aldave AJ, Kamal KM, Vo RC, Yu F. The Boston type I keratoprosthesis: improving outcomes and expanding indications. Ophthalmology. 2009 Apr;116(4):640-51. doi: 10.1016/j.ophtha.2008.12.058. Epub 2009 Feb 25.</citation>
    <PMID>19243830</PMID>
  </reference>
  <reference>
    <citation>Baltaziak M, Chew HF, Podbielski DW, Ahmed IIK. Glaucoma after corneal replacement. Surv Ophthalmol. 2018 Mar - Apr;63(2):135-148. doi: 10.1016/j.survophthal.2017.09.003. Epub 2017 Sep 18. Review.</citation>
    <PMID>28923582</PMID>
  </reference>
  <reference>
    <citation>Banitt M. Evaluation and management of glaucoma after keratoprosthesis. Curr Opin Ophthalmol. 2011 Mar;22(2):133-6. doi: 10.1097/ICU.0b013e328343723d. Review.</citation>
    <PMID>21191292</PMID>
  </reference>
  <reference>
    <citation>Cueva Vargas JL, Belforte N, Di Polo A. The glial cell modulator ibudilast attenuates neuroinflammation and enhances retinal ganglion cell viability in glaucoma through protein kinase A signaling. Neurobiol Dis. 2016 Sep;93:156-71. doi: 10.1016/j.nbd.2016.05.002. Epub 2016 May 6.</citation>
    <PMID>27163643</PMID>
  </reference>
  <reference>
    <citation>Crnej A, Omoto M, Dohlman TH, Dohlman CH, Dana R. Corneal inflammation after miniature keratoprosthesis implantation. Invest Ophthalmol Vis Sci. 2014 Dec 16;56(1):185-9. doi: 10.1167/iovs.14-15884.</citation>
    <PMID>25515579</PMID>
  </reference>
  <reference>
    <citation>Engel LA, Muether PS, Fauser S, Hueber A. The effect of previous surgery and topical eye drops for primary open-angle glaucoma on cytokine expression in aqueous humor. Graefes Arch Clin Exp Ophthalmol. 2014 May;252(5):791-9. doi: 10.1007/s00417-014-2607-5. Epub 2014 Mar 18.</citation>
    <PMID>24638257</PMID>
  </reference>
  <reference>
    <citation>Freedman J, Iserovich P. Pro-inflammatory cytokines in glaucomatous aqueous and encysted Molteno implant blebs and their relationship to pressure. Invest Ophthalmol Vis Sci. 2013 Jul 18;54(7):4851-5. doi: 10.1167/iovs.13-12274.</citation>
    <PMID>23788371</PMID>
  </reference>
  <reference>
    <citation>Burgos-Blasco B, Vidal-Villegas B, Saenz-Frances F, Morales-Fernandez L, Perucho-Gonzalez L, Garcia-Feijoo J, Martinez-de-la-Casa JM. Tear and aqueous humour cytokine profile in primary open-angle glaucoma. Acta Ophthalmol. 2020 Feb 11. doi: 10.1111/aos.14374. [Epub ahead of print]</citation>
    <PMID>32043817</PMID>
  </reference>
  <reference>
    <citation>Robert MC, Arafat SN, Spurr-Michaud S, Chodosh J, Dohlman CH, Gipson IK. Tear Matrix Metalloproteinases and Myeloperoxidase Levels in Patients With Boston Keratoprosthesis Type I. Cornea. 2016 Jul;35(7):1008-14. doi: 10.1097/ICO.0000000000000893.</citation>
    <PMID>27191670</PMID>
  </reference>
  <reference>
    <citation>Chen KH, Wu CC, Roy S, Lee SM, Liu JH. Increased interleukin-6 in aqueous humor of neovascular glaucoma. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2627-32.</citation>
    <PMID>10509659</PMID>
  </reference>
  <reference>
    <citation>Hu DN, Ritch R, Liebmann J, Liu Y, Cheng B, Hu MS. Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. J Glaucoma. 2002 Oct;11(5):406-10.</citation>
    <PMID>12362079</PMID>
  </reference>
  <reference>
    <citation>Kuchtey J, Rezaei KA, Jaru-Ampornpan P, Sternberg P Jr, Kuchtey RW. Multiplex cytokine analysis reveals elevated concentration of interleukin-8 in glaucomatous aqueous humor. Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6441-7. doi: 10.1167/iovs.10-5216. Epub 2010 Jun 30.</citation>
    <PMID>20592224</PMID>
  </reference>
  <reference>
    <citation>Dohlman CH, Zhou C, Lei F, Cade F, Regatieri CV, Črnej A, Dohlman JG, Shen LQ, Paschalis EI. Glaucoma After Corneal Trauma or Surgery-A Rapid, Inflammatory, IOP-Independent Pathway. Cornea. 2019 Dec;38(12):1589-1594. doi: 10.1097/ICO.0000000000002106.</citation>
    <PMID>31453878</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 6, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2020</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Boston keratoprosthesis type 1</keyword>
  <keyword>Glaucoma</keyword>
  <keyword>Aqueous Humor</keyword>
  <keyword>Tears</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Penetrating keratoplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

